Bristol-Myers Squibb Co.
NYSE:BMY 4:00:00 PM EDT
Products, Litigation
Bristol Myers Squibb Announces Settlement Of U.S. Patent Litigation For Revlimid (Lenalidomide) With Cipla
Published: 12/11/2020 12:11 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for Revlimid® (lenalidomide) With Cipla.
Bristol-myers Squibb - Cipla Licensed to Sell Volume-limited Amounts of Generic Lenalidomide in U.S. Beginning on a Confidential Date After March 2022.
Bristol-myers Squibb Co - Cipla Also Licensed to Sell Generic Lenalidomide in U.S. Without Volume Limitation No Earlier Than January 31, 2026.
Bristol-myers Squibb - Earliest Licensed Entry of Any Generic Lenalidomide in U.S. Continues to Be March 2022, Based on Settlements Reached.
Bristol-myers Squibb - Wholly Owned Subsidiary, Celgene, and Cipla Limited Have Settled Litigation Related to Patents for Revlimid.
Bristol-myers Squibb - Cipla's Ability to Market Lenalidomide in U.S. Will Be Contingent on Obtaining Approval of Abbreviated New Drug Application.
Bristol-myers Squibb - Cipla Licensed to Sell Volume-limited Amounts of Generic Lenalidomide in U.S. Beginning on a Confidential Date After March 2022.
Bristol-myers Squibb Co - Cipla Also Licensed to Sell Generic Lenalidomide in U.S. Without Volume Limitation No Earlier Than January 31, 2026.
Bristol-myers Squibb - Earliest Licensed Entry of Any Generic Lenalidomide in U.S. Continues to Be March 2022, Based on Settlements Reached.
Bristol-myers Squibb - Wholly Owned Subsidiary, Celgene, and Cipla Limited Have Settled Litigation Related to Patents for Revlimid.
Bristol-myers Squibb - Cipla's Ability to Market Lenalidomide in U.S. Will Be Contingent on Obtaining Approval of Abbreviated New Drug Application.